Emerging Technologies: New Antibody-Based Technologies
Article by Jennifer1661
Introduction
The therapeutic monoclonal antibody market, the industry’s fastest growing molecule type sector, is expected to maintain its impressive growth out to 2016. Within this market an emerging class of therapies will increase in importance over the coming six years, which will be introduced in this report. Additionally, the key companies and pipeline candidates for each technology will be profiled.
Features and benefits
* Gain insight into the sector’s outlook across the next 6 years* Analyze each technology’s pipeline candidates and the respective key companies involved
Highlights
Six new antibody-based technologies will be introduced with the key players for each of the technologies profiled. A full pipeline assessment of technology (from preclinical to late stage) will be provided. Finally, the market forecast for this emerging sector will be benchmarked with the entire prescription pharmaceutical market.
Table Of Contents
Emerging Technologies: New Antibody-Based Technologies
ABOUT THIS REPORT
PharmaVitae Explorer databaseChapter structureBiologics market dynamicsThe technologies and key playersProduct profilesData sourcingAnalyst consensus
EXECUTIVE SUMMARY
Key findingsIntroducing the new antibody-based technologiesThe development pipeline landscape of new antibody-based technologiesThe leading companies driving new antibody-based technology developmentNew antibody-based technology commercial return over 2010-16The MAb market will continue to be the fastest-growing sector across the entire pharmaceutical industry
BIOLOGICS MARKET DYNAMICS
Key findingsIntroduction to the PharmaVitae company universeThe prescription pharmaceutical market performance, 2010-16Prescription pharmaceutical market performance, 2010-16Biologics driven growth, 2010-16Introduction to molecule type analysisPrescription pharmaceutical market, by molecule type, 2004-16The MAb market will continue to be the fastest growing sector across the entire pharmaceutical industryNew antibody-based technologiesAntibody-drug conjugates will be the key driver in an emerging class
THE TECHNOLOGIES AND KEY PLAYERS
Key findingsOverview of the emerging antibody-based technologiesAntibody-drug conjugatesMylotarg’s withdrawal was a blow to the ADC marketOncology is the most active area of ADC developmentADC key playersSeattle GeneticsImmunoGenBispecific and trifunctional antibodies(Untitled sub-section)Trifunctional antibodiesDomain antibodies and nanobodiesDomain antibodies: GSK – through Domantis – leads the fieldAblynx’s nanobodiesFc-engineered antibodies
PRODUCT PROFILES
RemovabAdcetrisTrastuzumab emtansineInotuzumab ozogamicinGA101/RG-7159
APPENDIX
ReferencesDatamonitor researchExchange rates
LIST OF TABLES
Table: Number of pipeline candidates, by company, 2011Table: New antibody-based technology market launches, 2010-16Table: MAb market sales, by technology type ($ m), 2010-16Table: PharmaVitae company coverage, by peer setTable: Molecule type definitionsTable: General characteristics of small molecule drugs versus biologicsTable: Prescription pharmaceutical sales, by molecule type ($ m), 2010-16Table: MAb market sales, by technology type ($ m), 2010-16Table: Emerging technologies overview, 2011Table: Technology count by development stage, 2011Table: Antibody drug conjugate candidatesTable: Bispecific and trifunctional antibody candidatesTable: Domain antibody and nanobody candidatesTable: Antibody-drug conjugates candidatesTable: Removab: overviewTable: Adcetris: overviewTable: trastuzumab emtansine: overviewTable: inotuzumab ozogamicin: overviewTable: GA101/RG-7159: overviewTable: Exchange rates, 2011
LIST OF FIGURES
Figure: The PharmaVitae ExplorerFigure: New antibody-based technologies, preclinical-approved, 2011Figure: Total sales of the MAb market ($ m and %), 2004-16Figure: Proportion of sales of the MAb market from new antibody-based technologies (%), 2004-16Figure: The total pharmaceutical market outlook, sales ($ m) and year-on-year growth rate (%), 2004-16Figure: Total sales of the prescription pharmaceutical market ($ m), 2004-16Figure: Total sales growth of the prescription pharmaceutical market, by molecule type ($ bn), 2004-16Figure: Total sales of the MAb market ($ m and %), 2004-16Figure: MAb market sales, by technology type ($ m), 2004-16Figure: Technology count by development stage, 2011
Browse All Medical Devices Market Research Reports
http://www.reportsnreports.com/reports/134888-emerging-technologies-new-antibody-based-technologies.html
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Contact:
Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.com

